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Case presentation
A 41-year-old man was admitted to the Division of Nephrology,
Ospedali Riuniti di Bergamo, Bergamo, Italy. He reported vomiting,
watery diarrhea, abdominal pain, and dark urine for about one week. In
the following few days, he also noted oliguria, a 10 kg weight gain,
exertional dyspnea, severe headache, and visual disturbances. He had
moderate hypertension, which had never been treated. One year before
admission, laboratory tests performed to investigate headache and
lightheadedness had disclosed a serum creatinine of 1.3 mg/dl, protein-
uria of 2.7 g/24 hours, and I + occult blood in the urine. One month
before hospitalization, blood pressure had been 190/115 mm Hg.
On admission he had severe dyspnea and was anuric. Temperature
was 37.5°C; blood pressure, 230/150 mm Hg; heart rate, 100 beats/mm
and regular; and respiratory rate, 35/mm. Weight was 95 kg. Fundus-
copy showed hemorrhages and exudates. Inspiratory crackles were
heard over the posterior lung bases. The legs were markedly edema-
tous. Neurologic status was normal. Laboratory findings disclosed:
hemoglobin, 6.2 gldl; hematocrit, 16%; white blood cell count,
7000/mm3 (79% neutrophils); platelet Count, 25,000/mm3; reticulocytes,
15%; LDH, 3017 U/liter (normal, 50—150), and total bilirubin, 1.2 mg/dl
(unconjugated, 1.1 mg/dl). Haptoglobin was undetectable; fibrinogen
was 343 mg/dl; and fibrinogen degradation products were positive at 1:8
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• dilution. Microscopic examination of a stained blood film showed 20%
schistocytes. Serum creatinine was 20.5 mg/dl. Coombs test, HBsAG,
C-reactive protein, latex agglutination, and cryoglobulins were nega-
tive; erythrocyte sedimentation rate was 70 mm/hr. Stool examination
was negative for blood, leukocytes, salmonella, and pathogenic strains
of E. coli. The serum neuraminidase activity was normal. A chest x-ray
disclosed mild cardiomegaly and lung congestion. An abdominal radio-
graph was normal; the kidneys were 10 cm in length with regular
contours. Renal ultrasonography revealed no evidence of urinary
obstruction.
An open biopsy of the left kidney was performed. Histologic exam-
ination of the renal specimen revealed more than 50 glomeruli. By light
microscopy, glomeruli showed marked thickening of glomerular capil-
lary walls with subendothelial clear deposits and severe narrowing or
occlusion of capillary lumens (Fig. IA). Endothelial swelling and
occasional thrombi also were detected. Arterioles displayed diffuse
throwbotic changes associated with some areas of necrosis. Most
arterit s also were heavily involved with lesions characterized by intimal
and medial thickening, thrombosis, and necrosis (Fig. IB). Tubules
were atrophic and contained numerous casts. Diffuse interstitial inilam-
mation, edema, and fibrosis also were present. lmmunofluorescent
microscopy revealed focal mesangiocapillary 1gM, C3, and Clq depo-
sition, and abundant fibrin deposits along vascular basement mem-
branes. The clinical and histologic diagnosis was hemolytic-uremic
syndrome (HUS) in the course of malignant hypertension.
Daily hemodialysis was started, and packed red cells were transfused
during the first 2 dialysis treatments; fresh frozen plasma was infused at
each hemodialysis (about 800—1000 ml each time) for 20 days. One week
after admission the patient's symptoms improved. Edema and dyspnea
had resolved; blood pressure was 140/90 mm Hg. Platelet count was
250,000/mm3; hemoglobin, 11.1 g/dl; and hematocrit, 32%. Haptoglobin
was ISO nig/dI (normal, 100—300 mg/dl). Unfortunately, renal function
did not improve, anuria persisted, and the patient required chronic
maintenance hemodialysis. Rare schistocytes persisted in stained blood
films.
Four years after initial presentation, cadaveric renal transplantation
was performed. One week later serum creatinine was 1.7 mg/dl, and
blood pressure was 130/80 mm Hg. An acute rejection episode was
treated successfully with three daily pulses of methylprednisolone (500
mg/day), and the patient was discharged taking methylprednisolone (24
mg/day), azathioprine (150 mg/day), and spironolactone (100 mg/day).
He was well for 6 weeks postoperatively but was readmitted because of
a productive cough, dyspnea, and fever (37.5°C). Serum creatinine was
2.6 mg/dl; hemoglobin, 12 mg/dl; hematocrit, 35%; and platelet count,
213,000/mm3. The transplanted kidney was tender; an ultrasonogram
revealed it to be diffusely edematous. Blood pressure was 250/140 mm
Hg. In the following days, renal failure progressed; the fever increased
and the patient became severely dyspneic. Interstitial pneumonia was
diagnosed and 5-fluorocytosin, erythromycin, and cotrimoxazol were
administered. One week later the respiratory distress resolved, but the
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Fig. 1. A The glomerulus shows an almost complete occlusion of a large number of capillary lumina. Note: an arteriole with almost complete
luminal occlusion (trichrome, x 250). B The arteriole shows complete occlusion of the lumen due to endothelial swelling and myointimal
proliferation (trichrome, X 400).
serum creatinine was 7.5 mg/dl. Hemoglobin was 11 g/dl; hematocrit,
30%; and platelet count, 96,000/mm3. A peripheral blood smear dis-
closed typical fragmented erythrocytes. Plasma von Willebrand factor
high-molecular-weight components were unaltered. Despite treatment
with alpha-methyldopa, 500 mg/day, and nifedipine, 30 mg/day, blood
pressure remained high (190/120 mm Hg). Funduscopic examination
showed no papilledema, hemorrhages, or exudates.
A biopsy of the transplanted kidney revealed 6 glomeruli. Light
microscopy showed relatively mild glomerular changes characterized
by a slight thickening of the glomerular capillary wall and an increase of
mesangial matrix not associated with concomitant proliferation. Some
arterioles displayed intimal proliferation and thrombosis. The arterial
walls showed intimal and medial thickening; an interlobular artery was
completely obstructed by thrombosis. Tubulointerstitial changes were
mild. Electron microscopic examination disclosed a slight collapse of
the glomerular loops and a thickening of the lamina rara interna
associated with a moderate increase of mesangial matrix. In some
peripheral glomerular loops, doubling of the glomerular basement
membrane was seen with endothelial cell swelling and detachment from
the basement membrane. Arterioles showed myointimal proliferation
with lipid inclusions.
Recurrence of the hemolytic-uremic syndrome was diagnosed. Fresh
frozen plasma was infused for one week, and 6 plasmaphereses were
performed. Renal function partially recovered, and laboratory tests
suggested a remission of the hemolysis. Blood pressure decreased
without a change in the antihypertensive medications. At discharge, the
blood pressure was 160/100 mm Hg; serum creatinine, 3.8 mg/dl;
hemoglobin, 9.3 g/dl; and hematocrit, 27.6%. The platelet count was
412,000/mm3. The patient was taking methylprednisolone, azathioprine,
nifedipine, alpha-methyldopa, furosemide, and spironolactone.
Subsequently, renal function slowly and progressively deteriorated.
Five months after renal transplantation, the serum creatinine was 8
mg/dl and the blood pressure was 170/110 mm Hg. A peripheral blood
smear continued to show occasional fragmented erythrocytes. Hema-
tocrit was 28%; hemoglobin, 9.3 g/dl; and platelet count, 220,000/mm3.
Serum haptoglobin was decreased. The patient returned to chronic
maintenance hemodialysis. The patient is now well and no relapses
have occurred.
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Discussion
DR. GIUSEPPE REMUZZI (Head, Laboratory of Kidney Dis-
eases, Mario Negri Institute for Pharmacological Research,
and Associate Professor, Division of Nephrology and Dialysis,
Ospedali Riuniti di Bergamo, Bergamo, Italy): At the age of 41
years this man, with a history of moderately elevated blood
pressure, developed malignant hypertension and was admitted
with clinical and laboratory features of the hemolytic-uremic
syndrome (HUS). Renal biopsy showed severe arteriolar in-
volvement. A prompt remission of the hematologic abnormali-
ties occurred concurrently with control of the hypertension and
infusion of plasma. Renal function did not improve, however.
The patient was treated with chronic hemodialysis, and 4 years
later he underwent cadaveric renal transplantation. Two
months after transplantation, laboratory features and renal
biopsy findings suggested the recurrence of HUS in the trans-
planted kidney.
The initial presentation and clinical course of this patient are
typical of adult HUS because they occurred in the context of
severe hypertension. Indeed, in adults most cases of HUS are
secondary either to hypertension, to systemic diseases such as
lupus erythematosus and scleroderma, or to a variety of drugs
[I]. By contrast, in children HUS is most commonly associated
with viral or bacterial infections [2—51.
In this Forum I will first consider whether HUS and TTP
(thrombotic thrombocytopenic purpura) should be regarded as
two clinical manifestations of the same disease entity or as two
different diseases. I favor the former view, and I will use the
general term HUS/TTP to identify the broad spectrum of
clinical manifestations characteristic of this condition, including
hemolytic anemia of the microangiopathic type, thrombocyto-
penia, and renal failure with or without neurologic manifesta-
tions. Later in the discussion I will consider the most recent
hypotheses about the pathogenesis of this syndrome and briefly
discuss the various therapies proposed. The patient under
consideration here developed renal failure and then received a
renal transplant. The recurrence of the disease in the trans-
planted kidney will provide a springboard for some final com-
ments about "recurrent" HUS in renal transplants.
HUS and TTP: The same or different diseases?
The history of HUS/TTP began in 1925 with Moschcowitz'
report titled "An Acute Febrile Pleiochromic Anemia with
Hyaline Thrombosis of the Terminal Arterioles and Capillaries:
An Undescribed Disease" [6]. This report described a 16-year-
old girl with anemia, petechiae, fever and, notably, renal
involvement, The subsequent report on this syndrome by Baehr
et al in 1936 mentioned the concurrent presence of reticulocy-
tosis and thrombocytopenia in addition to severe anemia [7].
The syndrome reported by Gasser and coworkers in 1955 [81,
named the hemolytic-uremic syndrome, was in most respects
similar to that previously reported by Moschcowitz and Baehr
et al as thrombotic thrombocytopenic purpura. Gasser and
coworkers considered this new syndrome different from TTP,
however, because of the presence of severe renal failure. In
1966, however, Amorosi and Ultmann, in a review of 271
previously reported cases of TTP, found that 191 of the 217
cases in which proteinuria, hematuria, pyuria, casts, or
azotemia were recorded had evidence of renal involvement [9].
Although attempts have been made to differentiate HUS from
TTP [10, 11], I believe that none of the proposed differentiating
features can clearly separate these two clinical syndromes.
First, the notion that TTP is characterized by multiorgan
involvement, whereas HUS typically features isolated renal
involvement [10], does not stand up to close scrutiny; careful
evaluation of the cases reported so far clearly shows that this
distinction is not apparent in clinical practice. Second, the
fundamental pathologic lesion, thrombotic microangiopathy
[12, 13], is identical in HUS and TTP, although it can prefer-
entially involve different organs [14, 15]. Third, it was once
thought that, unlike TTP, HUS responded to heparin [10]. We
now know, however, that HUS also does not respond to
anticoagulants [16]. Fourth, the most widely utilized, classic
criteria for distinguishing the two syndromes, namely, the
presence of renal failure in HUS and of neurologic symptoms in
TTP, also may fail to separate these two conditions. Patients
with the clinical diagnosis of HUS can manifest neurologic
involvement [8, 17, 181, and a high percentage of patients
classified as having TTP have renal failure [6, 9, 19, 20]. On
occasion, an individual patient has been reported as having
HUS in one episode, and TTP during another [21—23].
Gianantonio and colleagues found cerebral microthrombi in
about one-half of 26 autopsied patients classified as having HUS
[17], and a recent report indicated neurologic involvement in 15
of 44 children with HUS [18]. Even though the most striking
clinical manifestation of HUS is renal damage, multiorgan
involvement (liver, pancreas, heart, brain, and muscles) is quite
common [15]. Similarly, the proportion of patients thought to
have TTP who have clinically apparent renal involvement
ranges in various series from 40% to 80%. Eknoyan and Riggs
reviewed the cases of TTP published between 1966 and 1986
[201. Data on renal involvement were recorded in 216 patients.
Some degree of renal involvement (ranging from abnormal
urinalysis to severe renal insufficiency) occurred in a large
percentage of patients (80%—90%). Of anecdotal interest in this
context is the observation that the patient reported by
Moschcowitz in the initial description of TTP had renal fail-
ure [61.
Thus, in the absence of criteria that can differentiate between
HUS and TTP, I favor the view that these terms describe
different clinical expressions of the same disease, a disease
characterized by microangiopathy, hemolytic anemia, renal
failure and, sometimes, neurologic involvement, A diagnosis of
this disease, which I shall term "HUS/TTP," should be enter-
tained whenever acute hemolytic anemia of the microangio-
pathic type is associated with thrombocytopenia and any degree
of renal damage. The key pathologic lesion is hyaline thrombo-
sis of small vessels; this change mainly involves the kidneys in
disorders previously called HUS, and the brain in disorders
previously called TTP [14, 24]. In young patients, renal failure
often dominates the clinical picture; this accounts for HUS
being the commoner term in the pediatric literature. In adults,
neurologic involvement often dominates, accounting for TTP
being the predominant diagnosis in this age group. In the
subsequent discussion, I will use the less restrictive term
HUS/TTP to describe this condition; when referring to previous
work of others, however, the terminology employed by the
respective author—either HUS or TTP—wilI be used in the
interest of fidelity.
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Classification
The clinical symptoms of HUS/TTP as well as its course,
prognosis, and response to treatment appear to be importantly
influenced by a number of factors, including age at onset,
geographic clustering of cases, and the type and severity of
underlying infections and/or systemic diseases. Even when
HUS/TTP occurs following the same causative agent and in
patients of the same age, the variability in individual response
can be marked and can result in markedly different clinical
features.
Several classifications have been proposed in an attempt to
identify subsets of patients with HUS/TTP with similar clinical
characteristics. The classification proposed by Drummond ap-
pears to be the most meaningful and comprehensive because it
takes into account not only the salient clinical features, but also
the various pathogenetic mechanisms thought to be operating in
the disease [1].
Using Drummond's scheme as a model, I propose classifying
HUS/TTP as follows:
(1) Infantile and childhood HUS/TTP. This form is not
associated with a recognized infectious episode, usually pres-
ents with a diarrheal prodrome, and has a good prognosis.
Vascular prostacyclin (PGI2) levels in these patients are gener-
ally normal, and glomerular thrombotic microangiopathy is the
characteristic pathologic feature.
(2) Hereditary and recurrent HUS/TTP. This form can occur
in children and adults and can follow a relapsing pattern.
Vascular PGI2 levels often are abnormal. Microangiopathy in
the kidney is predominantly arterial, and hypertension often is
severe.
(3) Postinfectious HUS/TTP. This form follows a clinically
obvious infection, can occur at any age, is usually due to
shigella, salmonella, E. coli, or streptococcus, and is sometimes
complicated by intravascular coagulation. Neuraminidase may
have a pathogenetic role.
(4) HUS/TTP accompanying systemic diseases. This form
comprises cases associated with systemic lupus erythematosus,
scleroderma, malignant hypertension, and radiation of the
kidney.
(5) HUS/TTP associated with pregnancy, or with the use of
oral contraceptives, cyclosporine A. or antineoplastic drugs.
The microangiopathy in these cases is predominantly arterial,
Clinical features and diagnostic criteria
Symptoms at presentation are markedly variable. Vomiting
or diarrhea prevail in the classic forms; furthermore, it is now
well established that patients with gastrointestinal prodromes
have a better prognosis than do those who present with upper
respiratory or urinary tract infections [1, 25, 26]. Hypertension
often is present; it is especially common in adult HUS/TTP and
in all secondary forms, particularly when a drug is the triggering
factor [27]. Occasional patients have neurologic involvement at
presentation, often after a few days of prodromal illness [17,
18]. These patients sometimes present with focal or generalized
seizures, transient hemiparesis, or even coma. Because of
thrombocytopenia, bleeding is frequent at presentation, often
involving the gastrointestinal tract [17]. Regardless of the main
symptoms at presentation, laboratory tests invariably indicate
anemia and a variable degree of renal involvement [15, 17].
Anemia is the result of nonimmunologic intravascular hemoly-
sis. The typical findings are increased bilirubin and LDH
enzymes, low haptoglobin, and reticulocytosis [17, 28]. Frag-
mented red blood cells with helmet and burr cells are visible in
the peripheral blood smear [29, 30]. Thrombocytopenia is
frequent, and is caused by peripheral destruction, as indicated
by a very short platelet survival time [31, 32]. No changes in
fibrinogen level or turnover have been documented in the
classic forms [31, 33]. Changes in other coagulation tests are
found less consistently. Prothrombin time can be prolonged and
levels of fibrin-dgradation products can be elevated, especially
in the forms of the disorder associated with bacterial infections
[17, 34—36]. Renal failure is reported in more than 90% of
patients [17], one-third of whom have anuria at presentation
[37]. Dialysis is required in a large percentage of patients [38,
39]. In surviving patients, the mean duration of renal failure is
14 days [17]. Gross hematuria is infrequent, but microhematuria
and proteinuria (ranging from I to 2 g/day) are quite common
[17]. The early complement components (C3, C4) may be
reduced [40—42], but the C5—C9 membrane attack complex of
complement generally is spared [28, 43].
Pathology
The pathologic changes originally described by Gasser and
coworkers in the kidneys of children with HUS were consistent
with cortical necrosis [8]. Since then the histology of this
condition has been described in more detail [13, 24, 44—46]. The
classic pathologic lesion of HUS/TTP, as described by Habib et
al [13], is thrombotic microangiopathy. Three patterns of renal
lesions have been described [47]. In the first, glomerular lesions
of the microangiopathic type predominate; in the second,
arterial involvement is prevalent; and in the third, both glomer-
ular and arterial involvement are evident. The glomerular lesion
is chartcterized by a thickening of the glomerular capillary
walls due to the presence of a "fluffy material" in the suben-
dothelial space. This pattern is associated with a widening and
fibrillar appearance of the mesangium, and with the presence of
occasional thrombi in the glomerular capillary lumina [48, 49].
The vascular distribution of lesions among various organs
differs widely [47, 50, 511 and, within the kidney, the percentage
of glomeruli affected also differs widely, thereby affecting the
outcome [47].
In young children, the lesions are mainly confined to the
glomeruli, and are characterized by thickening of capillary walls
and swelling of endothelial cells with narrowing or occlusion of
glomerular capillary lumina. Thrombi with the characteristic
staining for fibrin occasionally are seen. Red blood cells and
platelets can be seen in the glomerular capillary lumina. The
degree of arterial involvement is usually minimal, but some
widening of the subendothelial space containing fluffy material
is occasionally observed [47].
In older children and in adults, arterial changes are usually
more obvious [47, 52]. Thrombi are often present in the
interlobular arteries; the intima of these vessels is edematous,
and myointimal cell proliferation may be present [52]. If suffi-
cient time has elapsed, these lesions evolve to fibroplasia of
small arteries and, eventually, to sclerosis of arteries and
glomeruli. In some cases "glomeruloid" structures of the small
arteries are observed, which probably are the result of endo-
thelial and myointimal proliferation of small arteries adjacent to
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Fig. 2. Electron micrograph of a segment of glomerular capillary in a patient with HUSITTP. The cytoplasm of the epithelial cell is largely
separated from glomerular basement membrane. Electron-lucent "fluffy" material is present in the subendothelial space (x 3000).
the glomeruli [53]. Also present are glomerular ischemia, thick-
ening and wrinkling of the glomerular basement membrane,
atrophy of glomerular tufts, and thickening of Bowman's cap-
sule. In a small number of patients, the histologic pattern is that
of cortical or tubular necrosis. Occasionally, however, the
pattern of glomerular involvement coexists with significant
arterial damage in the same patient [47, 50]. Immunofluorescent
microscopy almost invariably demonstrates fibrinogen in the
glomerular thrombi, along the glomerular capillary walls, and in
vessel lumina [54], Granular deposits of both C3 and 1gM also
are found in most arterial walls [55, 56]. Electron microscopy
reveals swollen glomerular endothelial cells that often are
detached from the underlying glomerular basement membrane
(Fig. 2). Subendothelial, finely granular, electron-lucent fluffy
material, associated with a thin, newly-formed basement mem-
brane can be seen in the glomerular capillaries. This fluffy
material is thought by some to consist of breakdown products of
fibrinogen/fibrin as well as of fibronectin [531. The endothelial
and subendothelial changes result in marked narrowing of the
glomerular capillary lumena. Within the glomeruli, foam cells
containing lipid droplets and myelin figures appear relatively
late in the course of the disease. Edema of the mesangial
matrix, which leads to marked reticulation and even complete
dissolution, called "mesangiolysis" [57], is the most common
morphologic feature detected in the mesangium. Fibrin deposits
also can be present.
Pat hophysiology
Triggering events. The causative factor(s) resulting in
HUS/TTP have not been completely elucidated. In young
children, viruses and other microorganisms have been sus-
pected, because an association between the clinical manifesta-
tions of the syndrome and Coxsackie, ECHO, or adenovirus
infections has been noted [2—5]; cases classified as HUS also
have been reported in patients infected by microtatobiotes [23]
and yersinia [58]. Infection with endotoxin-producing bacteria
such as shigella [59] and salmonella [60] also has been proposed
as a cause. Karmali et al provided evidence for an association
between sporadic cases of HUS and E. coli infection [61]. E.
co/i produces a cytotoxin (Vero-cell cytotoxin, or Verotoxin)
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that can cause diarrhea and vascular damage, and which was
detected in the stool of 5 of 8 patients who were tested for its
presence. These findings suggest that the epidemic cases of
HUS/TTP reported during Shigella dysenteriae / infections
might have been due to a similar toxin. Several members of the
same family might be infected by a given agent but only one
develop the syndrome [62, 63]. Thus, one can infer that some
predisposing factor(s), independent of the triggering agent,
might be prerequisite for clinical expression of the disease.
In adults, the causes of HUS/TTP are more varied. In
addition to infectious agents, many other possible causative
factors have been recognized, including malignant hyperten-
sion, scleroderma, systemic lupus erythematosus, pregnancy,
radiation, and transplantation [641. We know that HUS/TTP
can occur in families [57, 65]. No genetic markers have yet been
identified, but the possibility of a dominant autosomal gene with
incomplete penetrance and variable expression as a mode of
inheritance has been suggested [65].
Of special interest is the association between HUS/TTP and
exposure to certain drugs. It has long been recognized that
HUS/TTP can occur in women taking oral contraceptives [66].
More recently reports have appeared of HUS/TTP in associa-
tion with immunosuppressive drugs, particularly mitomycin
[67—691 and cyclosporine [70, 711.
The role of lesions of vascular endothelium. All the factors
known to cause HUS/TTP are injurious to vascular endothe-
hum. This observation is in keeping with the concept derived
from morphologic data that endothelial damage constitutes the
key lesion in HUS/TTP [72]. Before discussing the possible
mechanisms of the disease, I will review briefly the physiology
of the interaction between vascular endothelium and intravas-
cular coagulation (Table 1).
Vascular endothelium is formed by a monolayer of flattened
polygonal cells, the long axes of which are oriented in the
direction of blood flow. Much of the current knowledge about
endothelial cell function derives from relatively recent studies
made possible by the availability of endothelial cell culture
techniques [73, 74]. One of the most important properties of
normal endothelium is the capacity to prevent thrombogenesis,
a capacity stemming from several factors that prevent reactivity
between vascular endothelium, on the one hand, and platelets
and the coagulation system, on the other [75, 761. Platelets as
well as endothelial cell membranes are negatively charged.
Thus mutual repulsion occurs and can contribute to endothelial
resistance to thrombogenesis by preventing platelets from ad-
hering to endothelium [77]. Moreover, vascular endothelial cell
membranes express a high-affinity thrombin receptor on their
surface. This receptor, referred to as thrombomodulin, is a
protein of 74,000 daltons that acts as a cofactor for the activa-
tion of plasma protein C by thrombin [78]. By forming a
complex with thrombin, thrombomodulin rapidly activates pro-
tein C, a potent inhibitor of coagulation factors VIII and V, and
thereby acts as a physiologic anticoagulant. In addition, endo-
thelial cells synthesize and release a number of factors that
interfere with hemostatic and thrombotic processes. One of
these factors is prostacyclin, which has vasodilatory properties
and is the most potent endogenous inhibitor of platelet aggre-
gation known [79]. It has a very short half-life (2 to 3 minutes),
breaking down by nonenzymatic degradation to the more stable
metabolite 6-keto-PGF1 a Prostacyclin inhibits platelet aggrega-
Table 1. Functional properties of normal vascular endothelium
1. Barrier selectivity
Endocytosis
Transendothelial channels
2. Thromboresistance
Negative charge (glycocalyx)
Uptake or degradation of PGF1, adenine nucleotides, brady-
kinin, angiotensin I, activated complement fraction 3
Protein C cofactor (thrombomodulin)
Antithrombin III cofactor (heparin sulfate)
Prostacyclin
Plasminogen activator
3. Synthesis
Factor Vill-related von Willebrand factor
Collagen type IV and Ill
Fibronectin
Prostacyclin
Thromboxane A2
15-HETE
Platelet activating factor
Plasminogen activator
Interleukin I
Endothelium-derived relaxing factor
Neutrophil chemoattractants
4. Growth
Mitogens: platelet-derived growth factor, fibroblast growth
factor, epidermal growth factor, brain-derived factor, liver
cell-derived factor
Inhibitors: cartilage extract, aortic extract, retinal extract,
heparin-binding fragments of fibronectin
lion by raising cyclic AMP levels in platelets [80, 81] and by
antagonizing the action of thromboxane A2 (TXA2). Thrombox-
ane, the production of which is catalyzed by platelet cyclooxy-
genase, has potent aggregating and vasoconstricting properties.
The balance between vascular PGI2 and platelet TXA2 is
thought to be an important mechanism in the control of
hemostasis and thrombosis. Any factor capable of altering this
balance disturbs the platelet-vessel wall homeostasis [78].
In contrast to previously held views, PGI2 appears not to
have important systemic antithrombotic activity [82—84]; its
circulating plasma levels are too low to inhibit platelet function
[85]. However, at the site of endothehial injury, PGI2 is likely to
be important in limiting thrombus formation because of its high
local concentration.
Plasminogen activator is another antithrombotic factor syn-
thesized and released by endothelial cells [86, 87]. It contributes
to thrombus dissolution at the site of injury by mediating
cleavage of a single bond in the zymogen to yield plasmin, a
very potent proteolytic enzyme. Endothelial cells, at least in
culture, also produce a fibrinolytic inhibitor that has the oppo-
site effect. This factor acts on urokinase-plasminogen activa-
tion, thus greatly reducing the fibrinolytic potential of vessel
walls [881.
Finally, endothelial cells synthesize and release into the
circulation von Willebrand factor (vWF); this large-molecular-
weight protein appears to play a pivotal role in mediating the
interaction of platelets with injuretl vessel walls [89]. Von
Willebrand factor, which circulates as a number of self-aggre-
gated multimers with molecular weights ranging from 0.5 to 12
million daltons [90], binds to specific receptors on the platelet
surface. Analysis of the spectrum of vWF multimers in various
hemostatic disorders has shown bleeding tendencies in the
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absence of higher-moleculer-weight forms and excessive plate-
let aggregates when larger multimers are present in plasma [911.
These observations suggest that the hemostatic activity of vWF
depends on the presence of the largest multimers.
Altered endothelial function. In view of the role of intact
vascular endothelium in preventing thrombogenesis, it is not
surprising that many factors suspected of being important in the
cause and pathogenesis of HUS/TTP have been examined for
their capacity to cause endothelial lesions. Bacterial endotoxins
can damage vascular endothelium [92—94]. Endotoxin-mediated
endothelial cell injury has been suspected as the cause of septic
shock in humans [95], and of the generalized Shwartzman
reaction in animals [96]. Indeed, when rabbit kidneys are
perfused with endotoxin, endothelial cell injury and cortical
necrosis result [97]. Furthermore, lipopolysaccharides derived
from Escherichia coli, Salmonella minnesota, and Salmonella
typhosa cause direct injury of bovine endothelial cells in culture
[98]. Cultured human endothelial cells show the same damage,
at least when protein synthesis is inhibited [99]. Neuraminidase,
produced by some bacteria and viruses, also can damage
vascular endothelium; Klein et al found that neuraminidase
exposes the Thomsen-Friedenreich receptors present on gb-
meruli, red cells, and platelets [100]. The formation of an
anti-Thomsen-Friedenreich 1gM antibody would promote ag-
glutination of red cells and platelets. Whether the anti-endothe-
hum antibodies occasionally found in some patients with
HUSITTP [101] also play a role in damaging endothelium in
some forms of the disorder merits further investigation.
Cyclosporine A and mitomycin, drugs that recently have
been associated with HUS, can directly cause endothelial
damage. Exposure of endothelial cells in culture to cyclo-
sporine A induces a time- and dose-dependent cell injury, which
results in cell detachment from the culture substrate and
subsequent lysis [102]. Perfusion of the renal artery with
mitomycin induces ultrastructural changes similar to those
found in patients with HUS [103]. The initial lesion is confined
to vascular endothelium, but is followed in short order by
deposition of platelets, obliteration of capillary lumina, and
lucent subendothelial expansion.
Pathogenesis of HUS/TTP
I believe that HUS/TTP is a clinical syndrome with many
possible causes, all of which initially act through the common
mechanism of inducing endothelial cell damage. This damage
triggers a cascade of biochemical events that ultimately leads to
the formation of thrombi in the microcirculation, and to the
clinical manifestations of the syndrome. The clinical features in
turn depend to a large extent on the specific organs involved
and on the extent of that involvement.
Because the secretion of PGI2 and vWF by endothelial cells
plays a pivotal role in modulating the interaction of the vessel
wall with circulating platelets, alterations in the production and
metabolism of these compounds in the pathogenesis of
HUS/TTP have been investigated. Our group reported that
vascular specimens obtained from adult patients with HUS/TTP
had a reduced capacity for P012 synthesis [104]. This finding
was subsequently confirmed by others and extended to children
[105—107]. Prostacyclin deficiency in HUS/TTP originally was
thought to be one of the factors favoring platelet activation and
deposition at the site of endothelial injury. However, the
observation that patients with HUS have a reduced capacity to
synthesize PGI7 apparently conflicts with experimental data
showing that endothelial damage stimulates rather than sup-
presses PG!2 production [108]. These apparently conflicting
observations can be reconciled: repeated stimulation of endo-
thelial cells by endotoxins might "exhaust" the vessel wall's
capacity to produce PGI2, as experimental evidence suggests
[109, 110]. Thus we hypothesize that P012 synthesis probably is
stimulated in the early phase of HUS, but depressed later when
more pronounced vascular damage takes place. Experimental
evidence also suggests that activation of the arachidonate
cascade following cell injury leads to the formation of lipid
peroxides, which are potent inhibitors of P012 synthetase [111].
In this connection, it is of particular interest that patients with
HUS may lack a factor present in normal plasma [104, 112,
1131, and which normally stimulates PGI2 [1141. This factor, a
stable, highly polar substance with a molecular weight of 300 to
400 daltons, protects the PGI2-forming system from inactivation
during chronic endothelial damage [1151. The observation that
remission in adult HUS sometimes occurs after infusion of fresh
frozen plasma [116, 117] is in keeping with the notion that
normal plasma contains a factor responsible for P012 synthesis.
Because the PGI2-regulating plasma factor behaves as a reduc-
ing cofactor for cyclooxygenase, plasma infusion may restore
the anti-oxidant potential of plasma, thus breaking the vicious
circle by which the disease progresses. This suggestion is
strengthened by the observation that 14 oliguric children with
HUS were successfully treated with vitamin E, a potent anti-
oxidant [118]. The discovery that normal serum binding of
prostacyclin is reduced in patients with TTP [1191 further
supports the concept of an overall reduction in P012 availability
at the site of vascular injury in this disease (Table 2).
Moake and coworkers suggest a role for abnormalities in
vWF metabolism in the pathogenesis of HUS/TTP [120]. These
authors demonstrated that unusually large vWF multimers were
present in the plasma of 4 patients with relapsing TFP during
clinical remission; the large plasma vWF multimers disappeared
during relapses. These findings were interpreted as indicating
that large vWF multimers, similar to those synthesized by
human cultured endothelial cells, are secreted by vascular
endothelium in patients with chronic relapsing TTP and that
these multimers persist in the circulation. Platelet activation
and adhesion at the site of vascular injury during relapse would
promote an in-vivo" interaction between platelets and the
large vWF multimers; as a result, the multimers would be
"consumed" in the microcirculation, and would no longer be
detected in circulating blood during the relapse. According to
Moake et a! [120] and others [121], the interaction between
platelets and large vWF multimers requires a triggering cofactor
that probably neutralizes the negative charge on circulating
platelets and favors the attachment of vWF multimers.
Patients with HUS also have abnormalities in Factor VIII and
in the composition of vWF multimers themselves. As early as
1974, an abnormally large amount of Factor VIlI-related anti-
gen was found by immunofluorescent localization in the glomer-
uli of patients with HUS [90]. This observation is consistent
with peripheral consumption of large vWF multimers. Further-
more, in 1984 Moake and colleagues reported decreased levels
of the largest vWF multimers during active HUS in 7 patients;
notably, the levels returned to normal during remission [122]. In
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Table 2. Plasma 6-keto PGF1, vascular generation of PGI2 and PGlrstimulating activity
Patient Plasma levels of Vascular generation PGI2-stimulating
Author Syndrome Age/sex 6-keto-PGF1 of PGI2 activity
Remuzzi 1978 [104] HUS 54/F Undectectable Decreased
56/F
Hensby 1979 [153] TTP 45/F Undetectable — —
Webster 1980 [105] HUS 31/F Decreased — —
Machin 1980 [154] TTP 27/F Undetectable — Absent
Wiles 1981 [155] HUS 19/F — — Decreased
Jorgensen 1981 [156] HUS 2/F — — Absent
Chen 1981 [157] TTP 39/M — — Normal
Defreyn 1982 [158] HUS 5/F — Undetectable Decreased
Levin 1983 [139] HUS 13 children — — Decreased in sporadic forms;
normal in epidemic forms
Stuart 1983 [107] HUS 4 mo/M — Undetectable Decreased
Walters 1985 [150] HUS 35 children — — Decreased in atypical forms
Stuart 1985 [151] HUS 5 children Increased — —
Turi 1986 [113] HUS 10 children — — Decreased or absent
Siegler 1986 [159] HUS 22 children — — Decreased
Hautekeete 1986 [160] HUS 36/F Increased — —
43/M
a Number in brackets is the reference number.
Table 3. Von Willebrand factor patterns in HUS/TTP
Author Syndrome Age/sex Plasma vWF patterns
Moake 1982 [120] Chronic relapsing TTP 31/F Unusually large multimers during remission that disappear
20/F during relapse
Moake 1984 [122] HUS 26/F Decreased large multimers at syndrome onset
61/M Decreased large multimers at syndrome onset
60/F Decreased large multimers at syndrome onset
5/F Decreased large multimers at syndrome onset
3/F Decreased large multimers at syndrome onset
3/M Decreased large multimers at syndrome onset
Rose 1984 [123] HUS 13 children Abnormally high-molecular-weight multimers during acute phase
of disease that fall with clinical improvement
Rowe 1985 [161] Chronic relapsing TTP 51/F Abnormally large multimers during remission following plasma
exchange or splenectomy that disappear during relapse
Moake 1986 [162] TTP 63/F Unusually large multimers at syndrome onset
a Number in brackets is the reference number.
addition to these quantitative abnormalities, Rose and cowork-
ers described qualitative changes in the vWF molecule of
patients with clinical HUS, namely an increase in the antigen
level and in high-molecular-weight multimers during the acute
phase [1231 (Table 3).
The large vWF multimers in the circulation probably origi-
nate in endothelial cells and platelets that normally contain
them. This possibility is consistent with the finding in some
patients with TTP of an IgG antibody that specifically binds to
endothelial cells, causes cell damage, and induces platelet
aggregation [1241. The isolation and purification from at least
some patients with TTP of a 37,000 dalton-molecular-weight
protein that is a potent agglutinator of normal platelets [1251
supports the notion that complex abnormalities in circulating
factors promote thrombus formation in the microcirculation of
these patients by interacting with platelets, von Willebrand
factor, and vascular endothelium.
These observations on the possible pathogenetic role of
abnormal vWF in HUS/TTP also are consistent with the previ-
ously recognized relationship between HUS and infection by
neuraminidase-producing agents such as Streptococcus pneu-
moniae [126]. Although many details about the pathogenesis of
HUS/TTP remain to be clarified, these observations taken
together suggest that in HUS/TTP the regulatory process that
normally prevents the largest vWF multimers from circulating
in the peripheral blood is impaired. The patterns of abnormal-
ity, however, might vary in different patients, and might depend
on the phase of the disease as well as on the relative activity of
microthrombosis in different individuals.
Therapy
Considerable improvement in the long-term prognosis for
patients with HUS/TTP has been observed in recent years [15,
25, 127] and is probably the result of better supportive manage-
ment of the acute phase of the disease. In children, the use of
blood transfusions, control of uremic symptoms, control of
hypertension, and appropriate treatment of electrolyte and
water imbalance have reduced mortality rates over the last 40
years from 40% to 50% to the current 4% to 13% [17, 1281. In
adults, however, HUS/TTP frequently still is a fatal disease;
mortality rates are as high as 50% [50, 129]. In adults, the
severity of the outcome usually depends on the degree of
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Table 4. Therapeutic approaches to HUS and TTP
HUS TTP
No. of Type of No. of Type of
Author patients study Author patients study
Steroids Amorosi 1966 [9]
Petitt 1980 [1711
Ridolfi 1981 [1271
Moake 1985 [1721
6
3
4
1
Uncontrolled
Uncontrolled
Uncontrolled
Heparin Kaplan
Brown
Gianantonio
Vitacco
Young Sorrenti
Proesmans
Ponticelli
1971 [130]
1973 [66]
1973 [171
1973 [1631
1978 [1641
1980 [16]
1980 [165]
67
3
26
33
4
30
11
Uncontrolled
Uncontrolled
Uncontrolled
Controlled
Uncontrolled
Controlled
Uncontrolled
Richardson 1968 [1731 1
Antiplatelet agents O'Regan
Ponticelli
Chow
1980 [51
1980 [165]
1986 [166]
11
4
Controlled
Uncontrolled
Uncontrolled
Ridolfi 1981 [127]
Rosove 1982 [174]
4
19
Uncontrolled
Uncontrolled
Splenectomy
Plasma infusion
Plasma exchange
Misiani
Stuart
Rizzoni
Remuzzi
Beattie
Spencer
Camba
Chow
1982 [117]
1983 [107]
1986 [138]
1979 [1161
1981 [141]
1982 [167]
1985 [168]
1986 [166]
17
1
32
2
1
1
4
4
Uncontrolled
Controlled
Uncontrolled
Uncontrolled
Uncontrolled
Baehr 1936 [7]
Cuttner 1980 [175]
Rowe 1985 [161]
Liu 1986 [176]
Byrnes 1981 [177]
Petitt 1980 [171]
Bukowski 1976 [178]
Byrnes 1977 [179]
Pisciotta 1977 [180]
Machin 1980 [154]
lacone 1985 [181]
ICGb 1986 [182]
1
18
1
8
18
5
13
1
9
1
4
22
Uncontrolled
Uncontrolled
Uncontrolled
Uncontrolled
Uncontrolled
Uncontrolled
Uncontrolled
Uncontrolled
Vincristjne Gutterman 1983 [169] 1 Abramson 1978 [183]
Gutterman 1982 [184]
Sennett 1986 [185]
1
5
4
Uncontrolled
Uncontrolled
Vitamin E Powell 1984 [118] 16 Uncontrolled
PGI2 Webster
Beattie
1980 [105]
1981 [141]
1
3 Uncontrolled
Hensby 1979 [1531
Budd 1980 [186]
FitzGerald 1981 [85]
Johnson 1983 [1871
Payton 1985 [188]
Guelpa 1986 [189]
1
1
1
3
1
2
Uncontrolled
Uncontrolled
Intravenous immuno-
globulin Wong 1986 [190]
Viero 1986 [191]
1
1
Staphylococcal protein
immunoperfusion Korec 1986 [1701 II Uncontrolled
a Numbers in brackets refer to the reference.b Italian Cooperative Group for the Study of TTP.
arterial involvement [50, 64, 130]. It is therefore not surprising
that the disease in the patient we are discussing today pro-
gressed rapidly to severe renal failure and required chronic
hemodialysis. Moreover, the disorder in adults often is second-
ary to systemic disease [64]. In such cases the severity of the
underlying disease and the multiorgan involvement probably
are the crucial factors responsible for the unfavorable outcome.
This concept also applies to the patient under consideration
here, who developed HUS/TTP as a complication of malignant
hypertension.
A variety of therapies has been proposed for HUS/TTP. A
critical analysis of the results is difficult, however, because the
number of prospective studies with adequate numbers of pa-
tients is few, and because different drugs and different drug
combinations have been used in the majority of reports (Table
4).
The use of heparin was abandoned in these patients alter a
prospective study in children showed that heparin alone or in
combination with antiplatelet agents did not influence the
short-term prognosis [16], Moreover, heparin carries consider-
able risks, particularly in patients with hypertension [1301.
Fibrinolytic agents do not improve the outcome of HUS/TFP
and may be harmful [131—133]. Antiplatelet agents such as
aspirin or dypiridamole do not appear to be beneficial in reports
of classic HUS [134, 135], but they have been of some apparent
value in reports of adult TTP [136, 137J. These observations are
not incompatible with the notion that HUS/TTP is a single
entity in view of the widely different age ranges included in the
reports and in view of the fact that none of the studies was
controlled.
Adult patients with HUSITTP have been treated with plasma
infusions with the aim of restoring the defective prostacyclin-
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stimulating factors [107, 116, 117]. This approach has given
some encouraging results with respect to long-term renal func-
tion [116, 1171. The number of patients treated in this fashion is
limited, however, and the lack of controlled studies makes
these observations difficult to evaluate. We used plasma infu-
sion in 10 children and 7 adults [117]. This treatment was
associated with rapid recovery from hematologic abnormalities
and from renal failure in all but 2 patients; both were adults with
particularly severe arterial lesions disclosed by renal biopsy at
admission. In these 2 patients the renal disease progressed and
chronic hemodialysis had to be instituted. On the basis of these
limited observations, we believe that plasma infusions might be
of value in slowing the progression of HUS/TTP in patients
presenting with severe vascular lesions. The discovery of
unusually large circulating vWF multimers in HUS [1231 pro-
vides another rationale for plasma infusions in this syndrome,
because plasma infusion could be expected to improve the
metabolism of vWF. We believe that plasma infusion acceler-
ates the hematologic remission in adult HUS/TTP, and thus
might help in the acute phase to prevent the most severe
complications related to thrombocytopenia, Whether patient
survival or long-term maintenance of renal function in adult
HUS/TTP is favorably influenced by plasma infusion, however,
is not definitely established.
Because HUSITTP in children generally has a good outcome,
it is not clear whether plasma infusion should be employed
routinely in this age group. In an effort to address this question,
Rizzoni et al recently performed a controlled trial in a group of
children [138]. The study showed that plasma infusions influ-
ence neither the acute mortality nor the long-term prognosis of
children with HUS/TTP. However, one of the problems in
evaluating the results of this study is that all the children
admitted to the study had a renal biopsy pattern of "predomi-
nantly glomerular type," which usually is associated with a
good prognosis. Whether plasma infusion would improve the
course of those pediatric cases of HUSITTP with unfavorable
prognostic signs (for example, sporadic HUS in older children,
gradual onset of the illness, absence of diarrhea, respiratory
rather than gastrointestinal prodrome) has not been determined.
It is noteworthy that prostacyclin-stimulating plasma activity
was normal in all the children admitted to the study, as in
children with the classic form of HUS and with predominantly
glomerular involvement at biopsy. The possibility that plasma
infusion is beneficial only in HUS/TTP of adults, and perhaps in
children with hereditary forms—in which a low PGI2-stimulat-
ing plasma activity can be documented [1391—needs to be
verified with adequate studies. Despite the claim that plasma
exchange can help occasional adult patients with HUS/TTP
(and sometimes dramatic effectiveness has been reported in
single cases), no proper trials have been performed; thus no
scientific basis exists at present for recommending the use of
plasma exchange. Theoretically, plasma exchange should have
some advantage over plasma infusion. Besides adding deficient
factors to the circulation, plasma exchange should be capable of
removing substances that could have an important role in the
pathogenesis of the disease. These include immune complexes,
fibrinolytic inhibitors, and various products of cell damage.
Moreover, the procedure of removing a patient's plasma with
an exchange transfusion might help eliminate from the circula-
tion the platelet aggregating factors recently found in HUS/TTP
[121, 125, 140] that are believed to play a role in the pathogen-
esis of the lesions.
In the last few years, infusions of PGI2 or of vitamin E have
been tried in HUS/TTP. The results with PGI2 have been
contradictory, and not enough data are available to support its
use [105, 141]. As I mentioned earlier, Powell et al achieved
encouraging results when they used vitamin E in 16 children
classified as having HUS [118]. A controlled trial is necessary to
establish the beneficial effects of this anti-oxidant in the treat-
ment of severe cases of adult HUS/TTP.
In summary, a few principles must be kept in mind for a
proper evaluation of the various therapeutic strategies in
HUS/TTP. I believe that the relatively good results reported in
the most recent series are primarily the consequence of the
improved general management of acute renal failure, rather
than the result of a beneficial effect of the various specific
therapeutic regimens used. The major remaining problem is to
identify effective treatment modalities for HUS/TTP in adults
with severe vascular involvement.
Patients who develop terminal renal failure require dialysis or
renal transplantation. Renal transplantation could be consid-
ered the therapy of choice, especially in children in whom
dialysis interferes with normal growth. However, the likelihood
of graft failure may be increased in patients whose renal failure
was secondary to HUS [63]. Cyclosporine A, the most potent
antirejection drug, can itself induce vascular changes resem-
bling those of idiopathic HUS/TTP [70, 142]. When given to
laboratory animals with acute serum sickness, cyclosporine A
induces glomerular lesions characterized by glomerular thrombi
and macroscopic infarction of the cortex [143]; these lesions
resemble those of HUS/TTP and are similar to those described
in humans as a rare complication of cyclosporine A therapy.
Reports of recipients of bone marrow [70], liver [142], and renal
grafts [144, 145] in which cyclosporine A was used to prevent
graft rejection suggest that such treatment might promote the
development of a syndrome characterized by thrombocytope-
nia, hemolytic anemia, and deteriorating renal failure. The
kidneys from these individuals showed glomerular and arterio-
lar lesions typical of thrombotic microangiopathy. The use of
cyclosporine A thus might not be advisable in patients with
HUS/TTP who receive a renal graft. In the absence of
cyclosporine A administration [146—1481, HUS/TTP can recur
after renal transplantation, as exemplified by the patient pre-
sented. Thus, the possible recurrence of the disease in the
allograft must be considered before proceeding to renal trans-
plantation in patients with HUS/TTP. A recent study by Hebert
and coworkers emphasized the high incidence of recurrent
HUS in children who received living-related-donor transplants
[148]. Of II patients whose original renal failure occurred
following HUS, 5 developed a recurrence of HUS in the
transplanted kidney. Pirson et al, however, were unable to
document recurrences of HUS among 12 children and 4 adults
who received a renal transplant [149]; one adult did have an
episode of acute, transient hemolysis 10 days posttransplant.
Thus the actual risk of recurrence in HUS/TTP patients receiv-
ing a renal graft is difficult to assess. Reports on this subject
conflict, probably because of the difficulty of differentiating
between the so-called recurrent HUS/TTP and severe acute
vascular rejection or malignant hypertension. Some criteria
might help in distinguishing between the two conditions. The
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presence of hemolytic anemia and thrombocytopenia may sug-
gest recurrent HUS/TTP rather than a form of rejection; how-
ever, cases of acute vascular rejection occasionally can have a
similar hematologic picture. Cases in which the disease occurs
months or years after transplantation, with an acute onset and
a rapidly progressive course, are more likely to be recurrent
HUS/TTP than vascular forms of rejection. Renal biopsy could
be of some value but cannot be regarded as providing a
definitive answer because the vascular changes of transplant
rejection can resemble the pathologic features of HUS.
Questions and answers
DR. FREDRIC COE (Chief, Renal Section, Mitchell Hospital,
Chicago, Illinois): As I understand your view, HUS and TFP
are the same disease and we should adopt a single name to
describe this condition. What I would like to address is the
differentiation between malignant hypertension and HUS/TTP,
or whatever that syndrome will now be called. When malignant
hypertension is present, what are the key factors that permit
one to know that there is more wrong with the patient than
simply the severe hypertension itself? A complete diagnosis is
difficult, as today's patient illustrates. Why couldn't the frac-
ture of red cells and consumption of clotting factors be occur-
ring because of the arteriolar damage from the malignant
hypertension? A very high blood pressure would lead me to
ascribe all the hemostatic disorders to the malignant hyperten-
sion. But in some patients the features of HUS/TTP are present
without malignant hypertension. I wonder whether we should
distinguish patients on the basis of the presence or absence of
hypertension rather than to separate TTP from HUS.
DR. REMuzzi: You might be right: it is difficult to say that in
patients with malignant hypertension the full expression of the
syndrome is not simply a consequence of hypertension. How-
ever, to my way of thinking, a patient who, in the course of
hypertension, develops microangiopathic hemolytic anemia,
thrombocytopenia, and renal failure would be classified as
having a form of HUS/TTP.
DR. JORDAN J. COHEN (Chairman, Department of Medicine,
Michael Reese Hospital, Chicago): Dr. Remuzzi, you placed
considerable emphasis on the role of a plasma factor that
stimulates prostacyclin production. You presented evidence
that prostacyclin production increased strikingly after the infu-
sion of normal plasma in 3 of your patients. Did those patients
improve clinically as their prostacyclin levels increased? Also,
have you tried to fractionate plasma in an effort to identify the
specific component responsible for stimulating prostacyclin
synthesizing activity? Assuming your hypothesis is correct, if
such a fraction could be prepared, it obviously would have
potential as a therapeutic modality in place of whole plasma
itself.
DR. REMuzzI: As far as the first question: yes, the patients
improved clinically as their PGI2 synthesizing activity in-
creased. Second: Deckmyn et al have provided details on a
partial isolation of the PG!2-regulating plasma factor [1151.
After ultrafiltration, normal human plasma was fractionated
through consecutive chromatographic separations and high-
performance liquid chromatography. At the end of this isolation
sequence, the factor was identified as a stable and very polar
molecule with an apparent molecular weight of 300 to 400
daltons.
Walters and coworkers carefully investigated plasma-factor
stimulating PGI2 in HUS [150]. These authors studied a large
group of children with HUS, and assessed the ability of their
plasma to support PG!2 production by rat endothelial tissue.
Normal PGI2 synthesis by endothelium incubated with HUS
plasma was found in the majority of cases of typical epidemic
HUS, whereas plasma from most children with atypical HUS
failed to support PG!2 production. It will be a challenge for
future studies to establish whether children with atypical HUS
and low PG!2-stimulating activity represent a subset of patients
more prone to develop the disease when exposed to environ-
mental triggers.
DR. SATISH KUMAR (Renal Fellow, University of Chicago):
Were the studies you quoted on the ability of plasma to
stimulate prostacyclin production performed on normal endo-
thelial cells?
DR. REMuzzI: Yes, all these studies are being performed
either on normal rat aortic rings or on normal vascular endo-
thelial cells of various origins (bovine endothelial cells, human
umbilical cord endothelial cells). It is now clear that not all the
patients with HUS/TTP have defective vascular PG!2 formation
[1511. Research is continuing to identify patients with this
defect in the hope of better clarifying the various expressions of
the disease.
DR. KUMAR: You presented impressive data for reduced
prostacyclin-stimulating activity in the plasma of patients with
HUS/TTP and for the correction of this deficit with infusion of
normal plasma. Don't these data indicate that the basic cause of
this syndrome is a deficiency of a circulating factor rather than
an abnormality of the endothelial cell?
DR. REMuzzI: Once endothelial damage develops as a con-
sequence of bacterial endotoxins or toxic drugs, for instance, a
number of mechanisms are activated that can limit the conse-
quences of cell injury. The PGI2-stimulating factor in plasma is
likely to behave as an important modulator of endothelial cell
function, A relative deficiency of PGI2-stimulating factor thus
might lead to the full development of the syndrome after the
initiating event has damaged endothelium. By analogy, plasma
levels of vitamin E, a potent anti-oxidant, can modulate the
course of HUS/TTP. As I already mentioned, deficient plasma
levels have been reported in association with the full develop-
ment of the syndrome, whereas therapy with high doses of
vitamin E can induce remission [1181.
DR. KUMAR: What is your current recommendation for
treatment of HUS/TTP? Do you recommend plasma exchange
in all patients?
DR. REMUZZI: Therapy depends very much on the severity of
the disease and the kind of organ involvement, For patients
with predominant renal involvement, the crucial issue is aggres-
sive general management of the renal failure, utilizing hemodi-
alysis or peritoneal dialysis, antihypertensive therapy, and
blood transfusions when anemia is symptomatic. It is likely that
the modern techniques for treating acute renal failure account
for the good results reported in recent years. Specific treatment
also needs to be considered. Patients with prolonged thrombo-
cytopenia may benefit from antiplatelet agents or PG!2. Adult
patients with the most severe forms of renal involvement with
oligoanuria and vascular lesions, as well as patients with
neurologic involvement who do not respond promptly to the
measures! have mentioned, should receive plasma infusion or
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plasma exchange. With plasma infusion, I suggest daily treat-
ment (8 to 12 units the first day, followed by 3 units daily) until
hematologic remission is achieved (that is, until the patient has
an increase in platelet count and a decrease in serum lactic
dehydrogenase). If proper facilities are available, plasma ex-
change can be used as an alternative to plasma infusion. Plasma
exchange has the advantage of restoring possible missing fac-
tors and simultaneol4sly removing from the circulation caus-
ative factors or other materials of cell damage and secretion.
Another advantage of plasma exchange is that it avoids volume
overload. Patients have been reported who failed to respond to
plasma infusion and who subsequently benefited from plasma-
pheresis.
In children, as I already mentioned, fresh frozen plasma
infusion did not influence short-term prognosis in a study by
Rizzoni and colleagues [1381. However, all the children ptrtic-
ipating in the study had typical HUS with only glomerular
lesions and normal plasmatic activity stimulating PG!2 synthe-
sis. Whether children with more severe lesions and with arte-
riolar involvement will benefit from plasma infusion remains to
be established.
DR. ANDREW ARONSON (Department of Pediatrics, Univer-
sity of Chicago): As a pediatric nephrologist, I am struck by the
great geographic difference in the occurrence of this condition.
For instance, on the south side of Chicago I see almost no
HUS/TTP, yet on the north side of this city and in other parts
of the country it is relatively common. Also, given the Minne-
sota experience [148], do you recommend or discourage living-
related-donor renal transplantation in your practice?
DR. REMuzzi: I agree with you: the occurrence of HUS/TTP
is influenced by environmental factors, and it is well known that
geographic differences exist in the expression of the disease.
The two most convincing examples of this geographic distribu-
tion are cases reported from Argentina by Gianantonio [17],
where most of the infants come from Buenos Aires and sur-
roundings, and by cases of HUS after shigellosis reported from
Bangladesh by Koster [59]. Reasons for the particularly high
incidence in some areas are not known.
Giving a renal transplant to patients with HUS has to be
considered with caution after the Minnesota experience [148].
Eleven patients whose original disease was HUS received 16
allografts. Recurrence of HUS was documented by renal biopsy
in 8 of the transplanted kidneys. The patient presented today
tends to support the view that HUS can recur after renal
transplantation, and a similar case was reported recently by
Strom [63]. Conversely, a preliminary report from Europe
found no recurrence of HUS in adults or children following
renal transplantation [149]. So far, our own experience with
adults and children with HUS/TTP who have undergone renal
transplantation also has been favorable.
DR. SERAFINO GARELLA (Renal Division, Michael Reese
Hospital): You make a powerful case for the clinical syndromes
of HUS and TTP being two extremes of the same disease. In
view of the fact that the major vasculotropic actions of PG!2 and
other prostanoids are exerted locally, rather than systemically,
are you suggesting that the differences in the clinical expression
of the disease that encompasses HUS and TTP might be due to
an influence of age or of other individual characteristics on the
production of PG!2 and/or thromboxane by the endothelial cells
of the involved organs? Are you aware of any experimental
observation that might support this hypothesis?
DR. REMUZZI: This is a very important point. It may be that
differences in the clinical expression of the disease are due to an
influence of age on the vascular ability to form PG!2. Vascular
PG!2 is defective in most adults with HUS/TTP in whom it has
been measured [104, 105], whereas it is normal in the majority
of children with the disease [151]. Studies are needed to
establish whether the localization of the disease in different
organs can be attributed, at least in part, to a local defect in
PGI2.
DR, MARK RICHTER (Renal Section, Mitchell Hospital): Does
the disease recur in patients who have not received transplants?
DR. REMUZZI: Yes; we don't know why it recurs in some
patients and not others. It is likely, as Kaplan suggested in 1975
[62], that hereditary factors might be operative, as evidenced by
documented recurrences in patients' siblings from non-endemic
areas. However, as yet no specific genetic defect has been
documented in these patients.
DR. COHEN: Are there animal models of this disease that
might be used to answer some of the remaining questions?
DR. REMuzzI: A generalized Shwartzman reaction can be
induced in rabbits by continuous intravenous infusion of endo-
toxin for 5 hours [152]. This maneuver induces platelet and
neutrophil activation with anemia and renal failure. The authors
suggest that this model resembles HUS in humans. This model,
however, does not closely resemble human HUS/TTP. Classic
microangiopathic lesions that appear in various organs of pa-
tients with HUS/TTP are not found in rabbits infused with
endotoxin; one finds only endothelial swelling with focal de-
tachment and some fibrin deposits in glomerular capillaries.
Cattell has reported a "hemolytic-uremic kidney" model in rats
in which one kidney was perfused with mitomycin [1031. This
model is characterized by initial endothelial damage followed
by widespread platelet thrombi in 24 hours. After one week, the
lesions resemble those in human HUS.
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